GE HealthCare has launched Prostate Volume Assist (PVA), an AI-driven solution designed to streamline and enhance prostate volume measurement in urology. This innovation is a significant advancement in the field, as accurate prostate volume calculations are crucial for diagnosing and treating prostate cancer effectively. PVA's AI-powered automation drastically reduces the time required for this process, providing results in less than two seconds. By expediting prostate volume measurement, urologists can make more informed treatment decisions promptly, ultimately improving patient outcomes.
Traditionally, determining prostate volume has been a manual and time-consuming task for urologists. However, with the introduction of PVA, this process becomes significantly more efficient and accurate. Leveraging artificial intelligence, PVA simplifies prostate volume measurement with just a single click, allowing urologists to allocate more time and attention to patient care rather than manual calculations. This technological advancement represents a significant step forward in prostate cancer management by facilitating earlier diagnosis and more precise treatment planning.
Moreover, the integration of PVA with GE HealthCare's existing product portfolio enhances workflow efficiency and complements their range of surgical visualisation and guidance solutions. By seamlessly integrating with ultrasound systems such as bkActiv, bk3000/5000, and bkSpecto, PVA further improves the capabilities of these devices in urology procedures. GE HealthCare plans to showcase this cutting-edge AI technology at upcoming industry events, underscoring its commitment to advancing prostate cancer diagnosis and treatment for better patient outcomes.
Click here to read the original news story.